Last Update: Apr 23, 2024
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies
ClinicalTrials.gov Identifier:
Novartis Reference Number:CLOU064A2303B
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 studies.

This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.

This is a global, multicenter, randomized, double-blind, placebo-controlled, randomized withdrawal Phase 3b extension study, followed by long-term open label treatment cycles to assess the efficacy, safety and tolerability of remibrutinib in adult participants with CSU inadequately controlled by H1-AH. The study comprises 2 Epochs. Epoch 1 is the initial study period for participants who completed preceding remibrutinib Phase 3 studies. Epoch 1 comprises of a 24-week randomized withdrawal period with remibrutinib or placebo for patients with UAS7<16 OR a 24 week Open-label treatment period with remibrutinib for patients with UAS7≥16.

Participants will be randomized in a 1:1 ratio to enter the double-blind placebo-controlled 24-week withdrawal phase. In case of relapse (UAS7≥16) in the blinded group, participants enter the (Re-)treatment period Epoch 1 and receive 24 weeks of Open-label treatment with remibrutinib. At the end of the (Re-)treatment period Epoch 1, participants will move to Epoch 2.

Epoch 2 is the second subsequent study period and consists of 24-week cycles that could either encompass treatment-free Observation and/or Open-label (Re-)treatment periods with remibrutinib, with or without background H1-AH.

In case of relapse (UAS7≥16) during an Observation period, participants enter the next (Re-)treatment period and receive 24 weeks of treatment with remibrutinib. Participants completing an Observation period 2/3/4/5 with a UAS7≤6 will complete the study. Participants with a UAS7 >6 -<16 can enter the next (Re-)treatment period if continuous treatment is considered necessary and beneficial for the individual participant. For participants with a UAS7<16 that enter the next (Re-)treatment period, remibrutinib monotherapy treatment (without background H1-AH) is required.

Chronic Spontaneous Urticaria
Phase 3
Recruiting
1021
Dec 09, 2022
Aug 10, 2027
All
18 Years - (Adult, Older Adult)

Interventions

Drug

LOU064 (blinded)

LOU064 (blinded) active treatment
Drug

LOU064 (open label)

LOU064 (open-label) active treatment
Drug

Placebo

Placebo

Eligibility Criteria

Inclusion Criteria:

Written informed consent must be obtained before any assessment is performed.
Male and female, adult participants ≥18 years of age.
Participants who successfully completed the preceding core studies CLOU064A2301, CLOU064A2302, CLOU064A1301, CLOU064A2304 or CLOU064A2305 according to the respective protocols.
Willing and able to adhere to the study protocol and visit schedule.

Exclusion Criteria:

Significant bleeding risk or coagulation disorders.
History of gastrointestinal bleeding.
Requirement for anti-platelet medication.
Requirement for anticoagulant medication.
History or current hepatic disease.
Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant.

Study Location

Novartis Investigative Site

Recruiting

Ranelagh, Partido De Berazate,Buenos Aires,1884,Argentina

Novartis Investigative Site

Recruiting

Santa Fe,S3000FIL,Argentina

Novartis Investigative Site

Recruiting

Buenos Aires,Nueve De Julio,B6500BWQ,Argentina

Novartis Investigative Site

Recruiting

Rosario,Santa Fe,S2000JKR,Argentina

Novartis Investigative Site

Recruiting

Caba,Buenos Aires,C1414AIF,Argentina

Novartis Investigative Site

Recruiting

Capital Federal,C1023AAB,Argentina

Novartis Investigative Site

Recruiting

Santo Andre,SP,09060 650,Brazil

Novartis Investigative Site

Recruiting

Ottawa,Ontario,K1G 6C6,Canada

Novartis Investigative Site

Recruiting

Verdun,Quebec,H4G 3E7,Canada

Novartis Investigative Site

Recruiting

Calgary,Alberta,T2M 1A6,Canada

Novartis Investigative Site

Recruiting

Edmonton,Alberta,T6G 1C3,Canada

Novartis Investigative Site

Recruiting

Shanghai,200443,China

Novartis Investigative Site

Recruiting

Hangzhou,Zhejiang,310003,China

Novartis Investigative Site

Recruiting

Guangdong,Guangzhou,510091,China

Novartis Investigative Site

Recruiting

Hangzhou,Zhejiang,310016,China

Novartis Investigative Site

Recruiting

Guangzhou,Guangdong,510515,China

Novartis Investigative Site

Recruiting

Guangzhou,Guangdong,510630,China

Novartis Investigative Site

Recruiting

Wuxi,Jiangsu,214002,China

Novartis Investigative Site

Recruiting

Shanghai,200040,China

Novartis Investigative Site

Recruiting

Barranquilla,080020,Colombia

Novartis Investigative Site

Recruiting

Bogota,110221,Colombia

Novartis Investigative Site

Recruiting

Medellin,Antioquia,050010,Colombia

Novartis Investigative Site

Recruiting

Barranquilla,Atlantico,080002,Colombia

Novartis Investigative Site

Recruiting

Praha 5,150 06,Czech Republic

Novartis Investigative Site

Recruiting

Olomouc,779 00,Czech Republic

Novartis Investigative Site

Recruiting

Copenhagen NV,2400,Denmark

Novartis Investigative Site

Recruiting

Hellerup,2900,Denmark

Novartis Investigative Site

Recruiting

Brest,29609,France

Novartis Investigative Site

Recruiting

Paris,75970,France

Novartis Investigative Site

Recruiting

Montpellier cedex 5,34295,France

Novartis Investigative Site

Recruiting

Reims,51100,France

Novartis Investigative Site

Recruiting

Angers 09,49933,France

Novartis Investigative Site

Recruiting

Pierre Benite,69495,France

Novartis Investigative Site

Recruiting

Antony,92160,France

Novartis Investigative Site

Recruiting

Toulouse,31400,France

Novartis Investigative Site

Recruiting

Rouen,76031,France

Novartis Investigative Site

Recruiting

Nice,06000,France

Novartis Investigative Site

Recruiting

Saint Mande,94160,France

Novartis Investigative Site

Recruiting

Bordeaux Cedex,33075,France

Novartis Investigative Site

Recruiting

Halle,06097,Germany

Novartis Investigative Site

Recruiting

Gottingen,37075,Germany

Novartis Investigative Site

Recruiting

Berlin,13187,Germany

Novartis Investigative Site

Recruiting

Luebeck,23538,Germany

Novartis Investigative Site

Recruiting

Berlin,13353,Germany

Novartis Investigative Site

Recruiting

Muenchen,80377,Germany

Novartis Investigative Site

Recruiting

Mainz,55131,Germany

Novartis Investigative Site

Recruiting

Muenchen,81377,Germany

Novartis Investigative Site

Recruiting

Marburg,35039,Germany

Novartis Investigative Site

Recruiting

Dresden,01307,Germany

Novartis Investigative Site

Recruiting

Bad Bentheim,48455,Germany

Novartis Investigative Site

Recruiting

Merzig,66663,Germany

Novartis Investigative Site

Recruiting

Halle (Saale),06108,Germany

Novartis Investigative Site

Recruiting

Leipzig,04103,Germany

Novartis Investigative Site

Recruiting

Bramsche,49565,Germany

Novartis Investigative Site

Recruiting

Debrecen,Hajdu Bihar,4026,Hungary

Novartis Investigative Site

Recruiting

Debrecen,4032,Hungary

Novartis Investigative Site

Recruiting

Milano,MI,20162,Italy

Novartis Investigative Site

Recruiting

Fukuoka,819 0167,Japan

Novartis Investigative Site

Recruiting

Seoul,03080,Korea, Republic of

Novartis Investigative Site

Recruiting

Seoul,03722,Korea, Republic of

Novartis Investigative Site

Recruiting

Gwangju,61469,Korea, Republic of

Novartis Investigative Site

Recruiting

Seoul,07061,Korea, Republic of

Novartis Investigative Site

Recruiting

Incheon,405 760,Korea, Republic of

Novartis Investigative Site

Recruiting

Lodz,90-265,Poland

Novartis Investigative Site

Recruiting

Poznan,60-693,Poland

Novartis Investigative Site

Recruiting

Bialystok,15 276,Poland

Novartis Investigative Site

Recruiting

Poznan,60-823,Poland

Novartis Investigative Site

Recruiting

Warszawa,02-507,Poland

Alma Cruz-Santana Private Practice

Recruiting

Carolina,Sandra Ortiz (+1 787 769 1954) email: [email protected] -- Alma Cruz,00985,Puerto Rico

Novartis Investigative Site

Recruiting

Cape Town,Western Province,7700,South Africa

Novartis Investigative Site

Recruiting

Pretoria,Gauteng,0009,South Africa

Novartis Investigative Site

Recruiting

Istanbul,34662,Turkey

Novartis Investigative Site

Recruiting

Samsun,55139,Turkey

Novartis Investigative Site

Recruiting

Izmir,35040,Turkey

Novartis Investigative Site

Recruiting

Talas / Kayseri,38039,Turkey

Novartis Investigative Site

Recruiting

Izmir,35140,Turkey

Novartis Investigative Site

Recruiting

Izmir,35380,Turkey

Novartis Investigative Site

Recruiting

Aydin,09100,Turkey

Novartis Investigative Site

Recruiting

Izmir,35620,Turkey

Novartis Investigative Site

Recruiting

Kayseri,38070,Turkey

Novartis Investigative Site

Recruiting

Sakarya,54290,Turkey

Novartis Investigative Site

Recruiting

Cardiff,CF14 4XW,United Kingdom

UCONN Health Dermatology

Recruiting

Farmington,Margaret Toro (860-679-4600) email: [email protected] -- Jun Lu,06030-2840 - Connecticut,United States

Florida Ctr Allergy Asthma Research .

Recruiting

Aventura,Aixa Valdes (305-273-2988) email: [email protected] -- Ileana Rodicio,33180 - Florida,United States

Antelope Valley Clinical Trials

Recruiting

Lancaster,Rose Warner-Castellanos (661-429-0100) email: [email protected] -- Ricardo Tan,93534 - California,United States

Oakview Dermatology

Recruiting

Athens,Leslie Lucas (740-566-4621) email: [email protected] -- Dawn Merritt,45701 - Ohio,United States

Northshore University Health System

Recruiting

Glenview,Madeline Snedden (847-663-6814) email: [email protected] -- Giselle Mosnaim,60077 - Illinois,United States

Allergy and Asthma Diagnostic Treatment Center

Recruiting

Tallahassee,(850-386-8034) -- Ronald H Saff,32308 - Florida,United States

Western Sky Medical Research

Recruiting

El Paso,Catherine Posey-Sarinana (915-544-2557) email: [email protected] -- Todd Funkhouser,79924 - Texas,United States

Arkansas Research Trials

Recruiting

North Little Rock,Hannah Anderson (+1 501 621 1100) email: [email protected] -- Scott Michael Dinehart,72117 - Arkansas,United States

Optimed Research LLC

Recruiting

Columbus,(614-430-8022) -- Donald Mcneil,43235 - Ohio,United States

Allergy and Asthma Specialist P S C

Recruiting

Owensboro,Andrea Arthur (270-684-6144) email: [email protected] -- Lee Clore,42301 - Kentucky,United States

Institute for Asthma and Allergy PC

Recruiting

Chevy Chase,Amie Koroma (301-962-5800) email: [email protected] -- Mark Scarupa,20815 - Maryland,United States

Asthma and Allergy Associates P C

Recruiting

Colorado Springs,Fellicia Grimes (719-473-8330) email: [email protected] -- Daniel Soteres,80907 - Colorado,United States

Orion Clinical Research .

Recruiting

Austin,(512-492-3797) -- William Howland III,78759 - Texas,United States

Allergy Associates of Utah

Recruiting

Murray,Maria Alcala (801-263-8700) email: [email protected] -- Andrew Smith,84107 - Utah,United States

John Hopkins University

Recruiting

Baltimore,Kelly Devine (410-938-3000) email: [email protected] -- Sarbjit S Saini,21204 - Maryland,United States

Bellingham Asthma Allergy and Immunology

Recruiting

Bellingham,(360-733-5733) -- David Elkayam,98225 - Washington,United States

RFSA Dermatology

Recruiting

San Antonio,Lindsey Finklea,78213 - Texas,United States

Allergy Asthma Assoc Monmouth

Recruiting

Little Silver,Laura Marini (732-741-8222) email: [email protected] -- Tina Zecca,07739 - New Jersey,United States

Kern Research

Recruiting

Bakersfield,Wandy Noriega (661-864-7710) email: [email protected] -- Eric Boren,93301 - California,United States

Toledo Institute of Clinical Research

Recruiting

Toledo,Faheem Husain (419-843-8815) email: [email protected] -- Syed Rehman,43617 - Ohio,United States

Deaconess Clin Allerg Res Inst

Recruiting

Evansville,Jessica Welchance (812-463-4793) email: [email protected] -- Anne Mclaughlin,47715 - Indiana,United States

Allervie Clinical Research

Recruiting

Birmingham,Justin Hall (205-209-4101) email: [email protected] -- John Anderson,35209 - Alabama,United States

Miami Dade Medical Research

Recruiting

Miami,Estela Neira (305-722-7210) email: [email protected] -- Vicente Chavarria,33176 - Florida,United States

AeroAllergy Research Laboratories of Savannah, Inc.

Recruiting

Savannah,Servon Jackson (912-356-3619) email: [email protected] -- Bruce Finkel,31406 - Georgia,United States

Treasure Valley Medical Research

Recruiting

Boise,Stacy Gonzales email: [email protected] -- Neetu Talreja,83706 - Idaho,United States

Finlay Medical Research

Recruiting

Greenacres City,Danelis Sanchez Perez (561-766-2181) email: [email protected] -- Jorge Calle Medina,33467 - Florida,United States

National Allergy and Asthma Research LLS

Recruiting

North Charleston,Vera Markovic (843-820-1036) email: [email protected] -- Patricia Gerber,29420 - South Carolina,United States

Allergy and Asthma Consultants

Recruiting

Redwood City,Sherry Lipson email: [email protected] -- Brian Lipson,94063 - California,United States

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals